Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077883 · ClinicalTrials.gov registry record · Phase 1
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Telik.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00077883 is a Phase 1 study that has completed, run by Telik. The registered enrollment target is 50 participants.
The verdict
NCT00077883, a Phase 1 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG TLK286, cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077883
The ClinicalTrials.gov registry entry for NCT00077883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TLK286, cisplatin is the first listed.
NCT00077883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077883 about?
NCT00077883 is a clinical study titled "TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)". The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT00077883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2004-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00077883?
The interventions under investigation include: TLK286, cisplatin (DRUG).
Who is sponsoring clinical trial NCT00077883?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.